China approves the world’s first CAR-T cell therapy for gastric cancer
China has approved Kaileimei (Satri-cel, CT041), the world’s first CAR-T cell therapy for solid tumors. The innovative CLDN18.2-targeted treatment offers a new option for patients with advanced gastric and gastroesophageal junction cancer who have failed at least two prior lines of therapy.
A New Step Forward: CAR-T Therapy for Gastric Cancer Included in China’s CSCO Guidelines
A new CAR-T therapy for advanced gastric cancer has been recognized in China’s national clinical guidelines, offering a potential new option for patients with limited treatment choices.
What Is CAR-T Cell Therapy? A Patient Guide to This Advanced Cancer Treatment in China
CAR-T cell therapy is an advanced form of immunotherapy that uses genetically modified immune cells to target cancer. This guide explains how CAR-T therapy works, who may benefit, the treatment process, and why China has become an important destination for CAR-T treatment and research.
CAR-T Cell Therapy for Multiple Myeloma
CAR-T cell therapy offers a groundbreaking solution for multiple myeloma. China provides world-class hospitals, skilled specialists, and personalized treatment to help patients achieve effective and safe outcomes.
CAR-T Cell Therapy for Leukemia
CAR-T cell therapy offers a revolutionary approach for treating leukemia. China provides world-class facilities, expert doctors, and personalized treatment plans to help patients achieve remission safely and effectively.
Relma-cel (Carteyva) Receives NMPA Approval for in Relapsed or Refractory Follicular Lymphoma
China expands CAR-T treatment options as relma-cel (Carteyva®) receives NMPA approval for relapsed or refractory follicular lymphoma, demonstrating high response rates in clinical trials.
NMPA Approval for Relmacabtagene Autoleucel (Carteyva) for Relapsed Large B-Cell Lymphoma
China approves relmacabtagene autoleucel (Carteyva®), a breakthrough CAR-T therapy for relapsed or refractory large B-cell lymphoma, offering new hope for durable remission.
China Approves First Cell Therapy Product, Opening a New Chapter in Cancer Treatment
Recently, China approved its first commercial cell therapy product—marking a major milestone in the country’s biopharmaceutical landscape.